EGFR and non-small cell lung carcinoma: Conversely, a meta-analysis of phase III studies comparing ICI monotherapy to docetaxel in the pretreatment setting revealed that ICI monotherapy is less beneficial in NSCLC patients with EGFR mutant compared to those of wild-type (58).